Associate Professor, Medicine, University of Colorado School of Medicine
Oncology
Dr. D Ross Camidge, MD
|
|
Give Review
Ross Camidge practices Oncology. He has 1 awards "CMS Meaningful Use Stage 1 Certification". Ross Camidge has written publications. He has 43 publications published with PubMed. The lastest publication is: 'Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.'
Publications
- NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.
- A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non-Small Cell Lung Cancer Clinical Trials: A Review of the Clinical...
- Alectinib in ALK-positive, crizotinib-resistant, non-small-cell Lung cancer: a single-group, multicentre, phase 2 trial.
- Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
- Buyer beware: understanding the assumptions behind health economic assessments in personalized Cancer care.
- Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non-Small-Cell Lung Cancer.
- Crizotinib effects on creatinine and non-creatinine-based measures of glomerular filtration rate.
- Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metasta...
- Clinicopathologic features and outcomes of patients with Lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
- Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer.
- Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations.
- A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non-Small-Cell Lung Can...
- Acquired resistance to TKIs in solid tumours: learning from Lung cancer.
- A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic ...
- Using multiplexed assays of oncogenic drivers in Lung cancers to select targeted drugs.
- Downstaging of Non-Small-Cell Lung Cancer Through Identification of Reversible Drug Toxicity.
- FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity Across All Lung Cancer Histologies.
- Ceritinib in ALK-rearranged non-small-cell Lung cancer.
- Atypical Negative ALK Break-Apart FISH Harboring a Crizotinib-Responsive ALK Rearrangement in Non-Small-Cell Lung Cancer.
- A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cel...
- Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lun...
- Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combinati...
- Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell Lung cancer treated with the ALK inhibitor crizotinib.
- Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group.
- Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.
- Native and rearranged ALK copy number and rearranged cell count in non-small cell Lung cancer: Implications for ALK inhibitor therapy.
- Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kin...
- Icotinib: kick-starting the Chinese antiCancer drug industry.
- Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies-results of a phase I dose-escalation study.
- Crizotinib versus chemotherapy in advanced ALK-positive Lung cancer.
- Initial Clinical Sensitivity and Acquired Resistance to MET Inhibition in MET-Mutated Papillary Renal Cell Carcinoma.
- Symptomatic reduction in free testosterone levels secondary to crizotinib use in male Cancer patients.
- Taking Aim at ALK Across the Blood-Brain Barrier.
- Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer.
- Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an ...
- A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell Lung cancer.
- Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell Lung cancer.
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell Lung cancer: updated results from a phase 1 study.
- Treating ALK-positive Lung cancer--early successes and future challenges.
- Targeted manipulation of apoptosis in Cancer treatment.
- Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer.
- Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell Lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
Schools
University Of Oxford Oxford Uk
John Radcliffe Hospital Oxford Uk
University Of Newcastle
Edinburgh University
Royal Postgraduate Medical School
University Of Oxford
PHD Molecular Biology Cambridge University
Conditions Treated
- Lung Cancer
- Pleura Cancer
- Pleural Neoplasm, Malignant
- Thymomas
Doctors Specialties
- Medical Oncology
- Oncology
- Thoracic Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- American Republic
- Pathway X Bronze Direct CACA IN HIX
- Anthem Blue Cross Blue Shield PPO
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Coventry Health Care
- First Health (Coventry Health Care) PPO
- Golden Rule
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- MVP Health Care
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
Hospital
-
University of Colorado Hospital
Helpful Reviews
Similar Doctors
|
Dr. Han Myint, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eamon M. Berge, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Anthony D. Elias, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Robert C. Doebele, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Jonathan A. Gutman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. L Michael Glode, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. Vibha T. Thomas, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Sami G. Diab, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jose I. Mayordomo, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Wells A. Messersmith, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Michael S. Guy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Angela M. Davies, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|